Quantbot Technologies LP Lowers Position in Lumentum Holdings Inc. $LITE

Quantbot Technologies LP decreased its position in shares of Lumentum Holdings Inc. (NASDAQ:LITE) by 24.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 69,178 shares of the technology company’s stock after selling 22,134 shares during the period. Quantbot Technologies LP owned about 0.10% of Lumentum worth $11,256,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Lumentum by 0.6% in the third quarter. Vanguard Group Inc. now owns 7,485,282 shares of the technology company’s stock worth $1,217,930,000 after purchasing an additional 41,975 shares during the period. Hood River Capital Management LLC boosted its holdings in shares of Lumentum by 82.1% during the 2nd quarter. Hood River Capital Management LLC now owns 2,206,453 shares of the technology company’s stock valued at $209,745,000 after buying an additional 994,551 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Lumentum by 0.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,260,940 shares of the technology company’s stock worth $119,884,000 after buying an additional 10,027 shares during the period. Channing Capital Management LLC increased its stake in shares of Lumentum by 61.0% in the 2nd quarter. Channing Capital Management LLC now owns 948,334 shares of the technology company’s stock worth $90,149,000 after acquiring an additional 359,394 shares in the last quarter. Finally, Schroder Investment Management Group lifted its position in Lumentum by 1.9% during the 2nd quarter. Schroder Investment Management Group now owns 881,813 shares of the technology company’s stock valued at $83,825,000 after acquiring an additional 16,200 shares during the period. Institutional investors own 94.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on LITE shares. Wolfe Research reaffirmed an “outperform” rating and set a $240.00 target price on shares of Lumentum in a research note on Wednesday, November 5th. Morgan Stanley raised their price objective on shares of Lumentum to $520.00 and gave the company an “equal weight” rating in a research note on Monday. Barclays upped their target price on shares of Lumentum to $475.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Raymond James Financial cut shares of Lumentum from a “strong-buy” rating to an “outperform” rating and set a $220.00 price target on the stock. in a report on Friday, October 31st. Finally, UBS Group boosted their price objective on shares of Lumentum from $215.00 to $455.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Lumentum presently has an average rating of “Moderate Buy” and a consensus target price of $458.00.

Lumentum Stock Up 3.5%

LITE opened at $700.91 on Friday. The firm’s 50 day simple moving average is $454.79 and its two-hundred day simple moving average is $291.42. The company has a market capitalization of $50.04 billion, a PE ratio of 215.00 and a beta of 1.51. Lumentum Holdings Inc. has a 1-year low of $45.65 and a 1-year high of $765.00. The company has a current ratio of 0.61, a quick ratio of 0.45 and a debt-to-equity ratio of 0.06.

Lumentum (NASDAQ:LITE) last posted its quarterly earnings data on Tuesday, February 3rd. The technology company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.41 by $0.26. The firm had revenue of $665.50 million during the quarter, compared to analyst estimates of $646.74 million. Lumentum had a return on equity of 17.27% and a net margin of 11.95%.Lumentum’s revenue was up 65.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.42 EPS. Lumentum has set its Q3 2026 guidance at 2.150-2.350 EPS. As a group, equities analysts forecast that Lumentum Holdings Inc. will post 0.03 EPS for the current year.

Insider Activity

In related news, insider Vincent Retort sold 45,026 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $591.32, for a total transaction of $26,624,774.32. Following the completion of the transaction, the insider directly owned 102,455 shares in the company, valued at approximately $60,583,690.60. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Penny Herscher sold 4,849 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $535.48, for a total transaction of $2,596,542.52. Following the completion of the sale, the director directly owned 6,057 shares of the company’s stock, valued at $3,243,402.36. This represents a 44.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 60,473 shares of company stock valued at $35,186,972 in the last ninety days. Corporate insiders own 0.43% of the company’s stock.

About Lumentum

Lumentum Holdings Inc, headquartered in San Jose, California, is a leading provider of photonic technologies that enable high-speed optical communication networks and advanced industrial applications. The company designs and manufactures a broad range of lasers, optical modules and subsystems tailored to the evolving requirements of telecommunications carriers, cloud data centers and enterprise networking.

Its core product portfolio includes tunable and fixed-wavelength laser transmitters, coherent optical engines, transceivers for long-haul, metro and data center interconnects, as well as test and measurement instruments.